Sign In
Buy MESO
$14.17
-0.380 (-2.61%)
At Close: Jul 31, 2026
Mesoblast Corporate Presentation at Investor Conference
08:23pm, Sunday, 02'nd Jun 2024
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference.
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
09:05pm, Monday, 29'th Apr 2024
FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexlemestrocel-L in End-Stage Heart Failure FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexl
Feeling Bold? 3 Aggressive Plays to 10X Your Returns by 2025
07:00am, Wednesday, 03'rd Apr 2024
For bold investors, there are few opportunities as exciting as chasing 10x returns in the stock market. Make no mistake about it, the stock market offers up multiple opportunities to turn $1 into $10
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
12:01pm, Wednesday, 27'th Mar 2024
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has infor
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
07:30pm, Wednesday, 13'th Mar 2024
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm co
NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA supports
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
05:57pm, Wednesday, 28'th Feb 2024
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and
Mesoblast Financial Results and Corporate Update Webcast
07:00am, Monday, 26'th Feb 2024
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States F
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
09:13pm, Tuesday, 30'th Jan 2024
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for th
Top 4 Health Care Stocks That May Explode This Month - Mesoblast (NASDAQ:MESO), Humana (NYSE:HUM)
07:03am, Friday, 26'th Jan 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
12:31pm, Friday, 19'th Jan 2024
Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.
REVASCOR Increases Size of Left Heart Chamber and Improves Surgical Outcomes in Children with Hypoplastic Left Heart Syndrome: Results Published in Journal of Thoracic and Cardiovascular Surgery Open
Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:18am, Friday, 05'th Jan 2024
Mesoblast Limited (MESO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in
